8-K: Salarius Pharmaceuticals Stockholders Approve Reverse Split and Equity Issuance for Nasdaq Compliance

Salarius Pharmaceuticals, Inc. stockholders approved a reverse stock split and the issuance of common stock to comply with Nasdaq listing rules at a special meeting held on July 8, 2025.

Summary

• A special meeting of stockholders was held on July 8, 2025, with 789,213 shares, or 37.10% of the 2,127,286 outstanding shares as of the May 13, 2025 record date, present or represented, constituting a quorum.
• Stockholders approved Proposal No. 1, the Reverse Stock Split Proposal, allowing the Board of Directors to effect a reverse stock split of the Common Stock at a ratio in the range of 1:4 to 1:40.
• Voting results for the Reverse Stock Split Proposal were 561,364 votes For, 224,901 votes Against, and 2,678 Abstentions.
• Stockholders approved Proposal No. 2, the Nasdaq 20% Issuance Proposal, for the issuance of shares of Common Stock pursuant to a securities purchase agreement dated December 12, 2024, with C/M Capital Master Fund, LP, to comply with Nasdaq Listing Rules 5635(a) and 5635(d).
• Voting results for the Nasdaq 20% Issuance Proposal were 124,631 votes For, 73,764 votes Against, 1,095 Abstentions, and 589,723 Broker Non-Votes.
• Stockholders approved Proposal No. 3, the Adjournment Proposal, which would have allowed for the solicitation of additional proxies if needed, but adjournment was not necessary as sufficient votes were obtained for the other proposals.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive because the company successfully obtained shareholder approval for critical corporate actions (reverse stock split and equity issuance) necessary for Nasdaq compliance and potential financing. While the need for these actions suggests underlying challenges (e.g., low share price, capital needs), the successful vote removes immediate hurdles and provides management with tools to address these issues.

Positives

• Stockholders approved the Reverse Stock Split Proposal, providing the Board with flexibility to address potential Nasdaq minimum bid price requirements.
• Stockholders approved the Nasdaq 20% Issuance Proposal, which is crucial for complying with Nasdaq listing rules and facilitating a previously agreed-upon equity financing with C/M Capital Master Fund, LP.
• Sufficient votes were obtained for both key proposals, negating the need for an adjournment of the Special Meeting.

Negatives

• The necessity of a reverse stock split often indicates a low share price, potentially below exchange minimums, which can be perceived negatively by investors.
• The high number of Broker Non-Votes (589,723) for the Nasdaq 20% Issuance Proposal suggests a significant portion of shares held by brokers did not vote on this specific matter, potentially indicating a lack of engagement or instruction from beneficial owners.

Risks

• Failure to maintain Nasdaq listing requirements, which the reverse stock split and equity issuance are intended to address, could lead to delisting.
• Potential dilution for existing shareholders from the issuance of new common stock under the securities purchase agreement.

Future Outlook

The approval of the reverse stock split provides the Board with the discretion to implement it at a future date and ratio (1:4 to 1:40), which is typically done to meet exchange listing requirements. The approval of the Nasdaq 20% Issuance Proposal facilitates the completion of a previously announced securities purchase agreement, indicating a path for future capital infusion.

Management Comments

• Mark J. Rosenblum, Executive Vice President & Chief Financial Officer, signed the report on behalf of Salarius Pharmaceuticals, Inc.

Industry Context

Reverse stock splits and equity issuances are common corporate actions for small-cap biotechnology and pharmaceutical companies, particularly those in clinical development stages, to maintain stock exchange listings and secure necessary funding for research, development, and operations. Compliance with exchange listing rules, such as minimum bid price requirements, is critical for maintaining investor visibility and access to capital markets.

Comparison to Industry Standards

• The approval of a reverse stock split with a broad range (1:4 to 1:40) is a standard mechanism for companies facing potential delisting due to low share prices, common among development-stage biotech firms.
• Seeking shareholder approval for equity issuances exceeding 20% of outstanding shares is a standard requirement under Nasdaq Listing Rules (5635(a) and 5635(d)) to prevent excessive dilution without shareholder consent, aligning with corporate governance best practices for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a change in the number of shares they own and the price per share if the reverse stock split is implemented, though the total value of their holdings should remain the same immediately after the split.
• Shareholders may experience dilution from the issuance of new shares under the securities purchase agreement.

Next Steps

• The Board of Directors will determine the exact ratio and timing, if any, of the reverse stock split.
• The company will proceed with the issuance of shares under the securities purchase agreement with C/M Capital Master Fund, LP, in compliance with Nasdaq rules.

Key Dates

Recommendation

Keywords

Salarius Pharmaceuticals, SLRX, Reverse Stock Split, Equity Issuance, Nasdaq Listing Rules, Special Meeting, Stockholder Vote, 8-K Filing, Corporate Governance, Capital Raise, Biotechnology, Pharmaceuticals